Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A simple blood test may help ER doctors better triage traumatic brain injury (TBI) patients. New research shows that measuring plasma levels of glial fibrillary acidic protein (GFAP) can identify patients with intracranial injuries that CT scans might miss. The findings, published in The Journal of Neurosurgery, could help hospitals manage overcrowding and direct the right patients to more advanced care.
CT scans have long been the go-to tool for assessing traumatic brain injuries (TBI), but they're not perfect — they can miss bleeds based on timing, bleed size, or location. New research published in The Journal of Neurosurgery suggests that a blood test measuring plasma biomarkers, particularly glial fibrillary acidic protein (GFAP), could give emergency physicians a powerful additional tool to triage TBI patients and decide who needs escalated care.
Researchers analyzed data from over 1,700 TBI patients in the TRACK-TBI observational study and found that GFAP levels within 24 hours of injury showed strong ability to distinguish patients with positive CT results from those with negative ones — outperforming the other biomarker tested, UCH-L1. Both biomarkers were most accurate when measured within 6 hours of injury.
By the Numbers:
Why it matters: In overcrowded EDs, faster and more accurate TBI triage can be life-saving. Blood biomarker testing could help clinicians confidently rule in or rule out serious brain injury, reducing unnecessary imaging while ensuring high-risk patients get timely neurosurgical attention.